Do Antenatal Steriods Affect Maturation of the Amplitude Integrated Electroencephalogram in Late Preterm Infants? A Secondary Study by the NRN for the MFMU ALPS Trial

Study ID
STU 032012-028

Cancer Related

Healthy Volunteers

Study Sites

  • Parkland Health & Hospital System

Diana Vasil

Principal Investigator
Lina Chalak, M.D.


The aLPS (antenatal Late Preterm Steriod Trial) being done with the niCHD Maternal Fetal Medicine units network is a randomized interventional trial to determine if ante-natal corticosteriods decrease the need for neonatal respiratory support among late preterm infants. Multiple other outcomes will be assessed including iVH, apnea, seizures, and encephalopathy as brain specific outcomes. Recent work from Women and infant's Hospital examined infants at the lower end of the late preterm range (34 0/7 to 34 6/7 weeks) and demonstrated that an immature amplitude integrated eeG (aeeG) pattern (less quiet sleep intervals) was associated with a longer hospitalization attributable to CnS dysfunction. The aLPS trial provides an opportunity to determine if ante-natal corticosteriods increase the frequency of quiet sleep intervals on an aeeG performed within 72 hours of birth and reduces the duration of neonatal morbidities.

Participant Eligibility

-mothers witha singleton pregnancy who are enrolled in the MFMU ALPS trial
-Gestational age limitation of 34 0/7 - 35 6/7 weeks